ITGR:NYSEInteger Holdings Corporation Analysis
Data as of 2026-05-19 - not real-time
$90.32
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Integer Holdings (ITGR) is trading at $90.32, with the 20‑day SMA just above the 50‑day SMA, indicating a mild short‑term upward bias while the 200‑day SMA remains higher, keeping the longer‑term trend neutral. The MACD line sits above its signal line, generating a bullish histogram, and the RSI at roughly 58 places the stock in the upper half of the neutral zone, suggesting limited upside pressure. Volume has been trending downward, and the current price sits just below the identified resistance around $91, which could cap near‑term gains. The beta of ~0.73 signals lower market volatility than the broader index, yet the 30‑day volatility of nearly 38% and a historic max drawdown of‑48% underscore the stock’s price swings. Recent material news shows Q1 sales essentially flat and full‑year revenue guidance modestly below consensus, but an Oppenheimer upgrade to Outperform adds analyst confidence.
Fundamentally, the trailing P/E of 22.4 is well under the industry average of 27.2, and the forward P/E of 13.3 points to meaningful earnings acceleration, supporting an undervalued classification. The price‑to‑book of 1.8 and upside potential of roughly 7.6% further reinforce the valuation case, while the lack of dividend makes income‑focused investors less interested. A solid operating margin of 8% and free cash flow generation indicate decent profitability, but the debt‑to‑equity of over 80% and a sizable debt load warrant caution. The Fear & Greed Index at “Extreme Greed” reflects strong market appetite, which could amplify short‑term moves. Overall, the blend of modest growth prospects, attractive valuation metrics, and manageable risk profile suggests a cautiously optimistic stance.
Fundamentally, the trailing P/E of 22.4 is well under the industry average of 27.2, and the forward P/E of 13.3 points to meaningful earnings acceleration, supporting an undervalued classification. The price‑to‑book of 1.8 and upside potential of roughly 7.6% further reinforce the valuation case, while the lack of dividend makes income‑focused investors less interested. A solid operating margin of 8% and free cash flow generation indicate decent profitability, but the debt‑to‑equity of over 80% and a sizable debt load warrant caution. The Fear & Greed Index at “Extreme Greed” reflects strong market appetite, which could amplify short‑term moves. Overall, the blend of modest growth prospects, attractive valuation metrics, and manageable risk profile suggests a cautiously optimistic stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD histogram
- RSI in upper neutral zone
- Proximity to resistance level
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued P/E relative to industry
- Forward P/E indicating earnings acceleration
- Analyst upgrade to Outperform
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Stable contract manufacturing position in medical devices
- Manageable debt with low beta
- Attractive valuation with upside potential
Key Metrics & Analysis
Financial Health
Revenue Growth0.50%
Profit Margin7.64%
P/E Ratio22.4
ROE8.58%
ROA4.23%
Debt/Equity81.41
P/B Ratio1.8
Op. Cash Flow$189.6M
Free Cash Flow$98.1M
Industry P/E27.2
Technical Analysis
TrendNeutral
RSI58.2
Support$77.05
Resistance$91.32
MA 20$86.59
MA 50$86.32
MA 200$87.84
MACDBullish
VolumeDecreasing
Fear & Greed Index89.21
Valuation
Target Price$97.22
Upside/Downside7.64%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.73
Volatility37.86%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.